Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 4:10 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 2,509 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sequence Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Na-GST-1 With or Without CpG

NCT02143518
View directory record Official record
Conditions
Hookworm Infection, Hookworm Disease
Interventions
Na-GST-1/Alhydrogel®, CpG 10104
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 3 Interventional Results available

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

NCT03573817
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Revefenacin, Placebo, Formoterol
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of D-allulose in Addition to Oral Sucrose Load

NCT02714413
View directory record Official record
Conditions
Blood Glucose
Interventions
D-allulose, sucrose, Placebo
Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers

NCT03901313
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A - 400 mg Fasting, Treatment B - 400 mg Fed, Treatment C - 200 mg Fed
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Estimate The Effect Of Lersivirine On The Pharmacokinetics Of S- And R-Methadone

NCT01099748
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Methadone, Lersivirine + Methadone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

NCT01402076
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tasimelteon, Rosiglitazone, Midazolam
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

NCT04887194
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Sitravatinib, Warfarin, Dextromethorphan, Midazolam, Digoxin, Rosuvastatin, Nivolumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Goshen, Indiana • Austin, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Nov 2, 2026, 4:10 PM EST
Active, not recruiting No phase listed Observational

Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks

NCT04975139
View directory record Official record
Conditions
Glioma
Interventions
RS-fMRI
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Clinical Evaluation of Approved Contact Lenses

NCT02540122
View directory record Official record
Conditions
Vision Disorders
Interventions
Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, Marketed Contact Lens 4
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)

NCT01953731
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib, Rifampin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Nov 2, 2026, 4:10 PM EST
Completed Not applicable Interventional Results available

Alcohol and Breast Cancer (ABC) Trial

NCT05423730
View directory record Official record
Conditions
ER+ Breast Cancer, Breast Cancer, Aromatase Inhibitors
Interventions
White Wine, Grape Juice
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 90 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional Results available

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

NCT01235728
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
MK-0873 2% Cream, MK-0873 vehicle (placebo) Cream, Calcitriol Cream
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fort Myers, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Nov 2, 2026, 4:10 PM EST
Completed Not applicable Interventional Results available

FMISO PET Study of Glioblastoma

NCT02076152
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
FMISO PET, MRI, Bevacizumab, CCNU
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Nov 2, 2026, 4:10 PM EST
Recruiting Phase 2 Interventional

Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG

NCT07611435
View directory record Official record
Conditions
Alpha-Gal Syndrome, Allergy
Interventions
DBFC with 150g of Alpha-gal Knock Out (KO) pork, DBFC with 150g of Wild Type (WT) pork
Diagnostic Test
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 50 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)

NCT06797674
View directory record Official record
Conditions
Healthy
Interventions
MK-7602, Efavirenz
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

NCT04139824
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Xanthine Oxidase Inhibitor, nonsteroidal anti-inflammatory drug
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Nov 2, 2026, 4:10 PM EST
Withdrawn Phase 2 Interventional

A Clinical Trial of PRAX-114 in Participants With Essential Tremor

NCT05387642
View directory record Official record
Conditions
Essential Tremor
Interventions
10 mg PRAX-114, 20 mg PRAX-114, and Placebo, 10 mg PRAX-114 or 20 mg PRAX-114
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Boca Raton, Florida • Farmington Hills, Michigan • Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants

NCT06092931
View directory record Official record
Conditions
Healthy Participants
Interventions
DC-806, Midazolam, Repaglinide, Digoxin, Rosuvastatin
Drug
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants

NCT02833831
View directory record Official record
Conditions
Healthy
Interventions
ALS-008176, Placebo, Moxifloxacin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 2, 2026, 4:10 PM EST
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Food Effect Study of Two Formulations of TAK-906

NCT04831502
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

NCT03438461
View directory record Official record
Conditions
Healthy
Interventions
Seltorexant 40 mg, Seltorexant 20 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Nov 2, 2026, 4:10 PM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Lu AG06479 in Healthy Young Men

NCT04473651
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06479, Placebos
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Taste Evaluation of Different Liquid Formulations With Eliglustat

NCT02422654
View directory record Official record
Conditions
Gaucher Disease
Interventions
eliglustat
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.

NCT03187496
View directory record Official record
Conditions
NASH
Interventions
Midazolam, Caffeine, Rosuvastatin, EDP-305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Nov 2, 2026, 4:10 PM EST